PROMOMED GROUP and the Government of the Kyrgyz Republic agreed on cooperation
Promomed 20 August 2021
A memorandum of cooperation in the pharmaceutical field between the Ministry of Investment of the Kyrgyz Republic and PROMOMED GROUP (Russian Federation) was signed on August 19, 2021 within the framework of the III Kyrgyz-Russian Business Forum. The subject of the memorandum is cooperation in the areas of pharmaceutical safety of the Kyrgyz Republic and provision of effective and safe antiviral agents for Kyrgyz citizens to combat the pandemic.
The solemn signing was attended by: the Minister of Investments of the Kyrgyz Republic Almambet Shykmamatov and General Director of Promomed DM LLC Maxim Smagin.
The parties agreed to join efforts to supply drug products to the Kyrgyz Republic, which are manufactured on the basis of modern innovative technological solutions in compliance with the Eurasian GMP standards and have high and proven efficiency. The memorandum also confirms the intention of the Russian party to transfer pharmaceutical production technologies to the newly created joint venture and to support it in research and production.
In addition, thanks to the agreement reached, one of the largest Russian universities, the Ogarev Mordovia State University, will open the opportunity for students from Kyrgyzstan to get a university degree education at the Department of Chemistry and Technology of Physiologically Active Substances, created with the support of the Promomed Group. The unique position of the department includes close cooperation with the Biokhimik pharmaceutical plant (part of the Promomed Group), internships for students at the real enterprise, the opportunity to practice in laboratories and workshops.
In addition, thanks to the agreement reached, one of the largest Russian universities, the Ogarev Mordovia State University, will open the opportunity for students from Kyrgyzstan to get a university degree education at the Department of Chemistry and Technology of Physiologically Active Substances, created with the support of the Promomed Group. The unique position of the department includes close cooperation with the Biokhimik pharmaceutical plant (part of the Promomed Group), internships for students at the real enterprise, the opportunity to practice in laboratories and workshops.
The signing of cooperation documents is the result of a meeting in May 2021 between the President of the Russian Federation Vladimir Putin and the President of the Kyrgyz Republic Sadyr Japarov. During the conversation, Vladimir Putin said: «We are also cooperating in the fight against the pandemic. Russia provides and intends to provide further support to Kyrgyzstan in the supply of test systems, antiviral drugs and vaccines.»
Based on the signed document, guided by its spirit and provisions, the parties will determine a company that will be certified by the Russian party as an exclusive dealer of Areplivir in the territory of the Republic of Kyrgyzstan with the possibility of potential expansion of the territory.
According to the memorandum, supplies of drugs developed and manufactured by Promomed Group at the Biokhimik site in Saransk will be carried out. On May 28, 2021, the parties agreed on this in Moscow (insert the link to the press-release on the first signing).
According to the memorandum, supplies of drugs developed and manufactured by Promomed Group at the Biokhimik site in Saransk will be carried out. On May 28, 2021, the parties agreed on this in Moscow (insert the link to the press-release on the first signing).
Minister of Investments of the Kyrgyz Republic Almambet Shykmamatov noted: «The pandemic has become a challenge for the national healthcare systems in all countries and the Kyrgyz Republic is no exception. We analyzed the potential of international drug developers very closely before making a choice. The Russian company Promomed is not only the undisputed leader in the development of drugs to control infections, but also the owner of one of the most innovative and powerful pharmaceutical production bases. I welcome our new partners and I am confident in the success of cooperation for the benefit of the people of Kyrgyzstan.»
The General Director of Promomed DM LLC Maxim Smagin commented: «One of the values in our company, Significance, means that we focus our efforts on solving really critical problems of medicine. The new coronavirus infection that swept the world is an example of such a challenge. I am proud that our medicines help save the lives of people in Russia, and thanks to the memorandum signed today, they will help the people of the Kyrgyz Republic in the fight against the pandemic.»
PROMOMED GROUP one of the leaders of the Russian pharmaceutical industry and an active participant in the national drug safety system. The company develops, manufactures and promotes up-to-date medicines, focusing its efforts on increasing the effectiveness and improving the safety profile of therapy for the most important diseases, including socially significant ones. Having the powerful biotechnological platform, the Biokhimik JSC (became part of the Group in 2015), which operates in full compliance with GMP standards, the Group is able to quickly and efficiently develop and produce any innovative drugs. Promomed portfolio includes about 200 types of drugs, 80% of which are included in the VED list and in the list of the guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health. The volume of production in 2020 amounted to 61 million packages of drugs for various purposes. At the end of 2020, the Expert RA rating agency assigned the non-financial company PROMOMED DM LLC a long-term credit rating ruBBB+.
PROMOMED GROUP one of the leaders of the Russian pharmaceutical industry and an active participant in the national drug safety system. The company develops, manufactures and promotes up-to-date medicines, focusing its efforts on increasing the effectiveness and improving the safety profile of therapy for the most important diseases, including socially significant ones. Having the powerful biotechnological platform, the Biokhimik JSC (became part of the Group in 2015), which operates in full compliance with GMP standards, the Group is able to quickly and efficiently develop and produce any innovative drugs. Promomed portfolio includes about 200 types of drugs, 80% of which are included in the VED list and in the list of the guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health. The volume of production in 2020 amounted to 61 million packages of drugs for various purposes. At the end of 2020, the Expert RA rating agency assigned the non-financial company PROMOMED DM LLC a long-term credit rating ruBBB+.
